PubMed · last 30 days

Peptide research index

An automated bibliographic list from NCBI E-utilities (PubMed). It is not medical advice, not a review, and not an interpretation of results. Records are grouped by search term. Only title, journal, publication date, first author, and the PubMed link are shown.

Source: PubMed via esearch and esummary, database pubmed, sorted by date, approximately forty records across the listed compounds. This page refreshes weekly. Compounds: BPC-157, thymosin beta-4, semaglutide, tirzepatide, retatrutide, cagrilintide, ipamorelin, sermorelin, GHRP-6.

14 records · fetched 2026-09-27 UTC

Semaglutide

Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
Internal and emergency medicine · 2026 Sep 26 · Ayyaz F et al.
Renal AA amyloidosis associated with severe obesity: improvement in kidney function and proteinuria following semaglutide-associated weight loss.
Journal of nephrology · 2026 Sep 26 · Atay I et al.
Estimating the carbon footprint of oral semaglutide (Rybelsus): a comparative analysis of the medicine carbon footprint model and manufacturer life-cycle assessment in pharmaceutical production.
BMJ open · 2026 Sep 24 · Hansell L et al.
Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications.
The journal of prevention of Alzheimer's disease · 2026 Sep 24 · Cummings JL et al.
Predictors of Peak Body Weight Loss With Semaglutide in the SELECT Trial.
Diabetes care · 2026 Sep 24 · Lingvay I et al.
Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial.
European heart journal · 2026 Sep 23 · Colhoun HM et al.
Semaglutide mechanisms of action: the missing pieces.
European heart journal · 2026 Sep 23 · Verma S et al.
Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease.
Advances in therapy · 2026 Sep 23 · Amamoo J et al.
Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome.
Medical sciences (Basel, Switzerland) · 2026 Sep 19 · Ravić MP et al.
Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review.
International journal of molecular sciences · 2026 Sep 10 · Cautela D et al.
Semaglutide Attenuates Inflammatory Macrophage Polarization and Promotes Changes Associated with Mitochondrial Biogenesis Through cAMP-Dependent Signaling.
Biomedicines · 2026 Sep 3 · Pavshintsev VV et al.

Tirzepatide

GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework.
Journal of clinical medicine · 2026 Sep 20 · Kaltsas A et al.
Pulsatile liraglutide on a biased tirzepatide background: a hypothesis.
Frontiers in endocrinology · 2026 Sep 10 · Kopitovic I

Retatrutide

Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework.
Biomedicines · 2026 Aug 31 · Kaczynski MM et al.